The majority of AYAs with liposarcoma had a “myxoid” variant, characterized by a t(12:16)(q13;p11) translocation, resulting in the formation of a FUS-CHOP fusion oncoprotein (rarer aberrations include t(12;22)(q13;a12) resulting in DDIT3-EWSR1 fusion protein).37 AYAs with myxoid liposarcoma had a favorable outcome compared with many other STS subtypes, explained by the disease biology and sensitivity both to chemotherapy and radiotherapy. Here, FUS is linked to myxoid liposarcoma.